The University of Chicago Header Logo

Connection

Hannah Ryles to Receptor Protein-Tyrosine Kinases

Back to Details
This is a "connection" page, showing publications Hannah Ryles has written about Receptor Protein-Tyrosine Kinases.
Hannah Ryles
Connection Strength
0.365
Receptor Protein-Tyrosine Kinases
  1. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. Clin Cancer Res. 2017 Jun 01; 23(11):2856-2868.
    View in: PubMed
    Score: 0.121
  2. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107.
    View in: PubMed
    Score: 0.112
  3. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94.
    View in: PubMed
    Score: 0.105
  4. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res. 2016 Feb 15; 22(4):948-60.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.